Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.41 |
| ▸ | CNR1 | P21554 | 10/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11445241 | 0.87 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL18516974 | 0.85 | HTR2A (0.40) | LMNAHTR2AHTR2CADRA1AOPRK1 | |
| SCHEMBL11216774 | 0.85 | CNR2 (0.43) | CNR2CNR1 | |
| SCHEMBL678356 | 0.79 | CNR1 (0.50) | CNR2CNR1TSHRTDP1 | |
| SCHEMBL22435799 | 0.79 | CNR2 (0.41) | CNR2CNR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25007218 | 0.79 | CNR2 (0.54) | CNR2CNR1KDM4ECYP1A2CYP2C19 | |
| SCHEMBL7174292 | 0.79 | CNR2 (0.54) | CNR2CNR1KDM4ECYP1A2CYP2C19 | |
| SCHEMBL8016745 | 0.79 | CNR2 (0.41) | CNR2CNR1 | |
| SCHEMBL10594862 | 0.79 | CNR2 (0.41) | CNR2CNR1KCNH2 | |
| SCHEMBL10612655 | 0.79 | RECQL (0.43) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10869860-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10869860-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | CNR2 27/4885CNR1 17/4885KDM4E 1313/4885 |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | CRBN, CBFB, CNN2 | CNR2 27/4885CNR1 17/4885KDM4E 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.